Abstract
The effect of etizolam, a thienodiazepine, was compared with that of a placebo in a double-blind controlled study of patients with vertigo.
1) The final global improvement rate in the etizolam group was moderate to excellent in 52.4%, and slight to excellent in 81.0%.
The final global improvement rate in the placebo group was excellent in 18.8% and slight to excellent in 56.3%, and worsening of vertigo occurred in 12.5 % of the placebo group. The difference between the two groups are significant.
2) Etizolam was significantly more effective than placebo in treating patients with anxiety.
3) Etizolam was significantly more effective than placebo for non-rotatory vertigo in the first and second weeks of treatment.
4) Side-effects were observed in 12.5% of the etizolam group and in 25.0% of the placebo group, not a significant difference. None of the side-effects were severe.
5) The global utility rate of etizolam was significantly greater than that of placebo.
